Return to the full list of Biomarkers
Orientation
Method of Measurement (Pre-analytical Tools)
Imaging
Biomarker Measured
Unknown
Use
Pharmacodynamic/response
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results
Establish orientation as core disturbance in AD by collecting, coregistering, and analyzing Positron Emission Tomography (PET) and , functional and structural magnetic resonance imaging (MRI, fMRI) data from AD-spectrum patients.
Target Population/ Population Being Studied
Patients with Amnestic MCI or AD and healthy controls
Length of Current Trial
1 day?
Number of Trial Participants
30
Estimated Trial Completion
February 2020
What is Required from Patients
injection of radioactive tracers, mild discomfort, entering an fMRI machine (can induce claustrophobia), in clinic visit
What is Required from the Health System
PET technician, fMRI technician, fMRI machine, PET scanner, dyes
Sponsor
Assuta Medical Center; Hadassah Medical Organization
“Orientation in AD Patients: PET-MR Study.” ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT03030365?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=11&rank=92